Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 15/20 | 0.49 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | OXTR | P30559 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6538906 | 0.89 | PPARD (0.49) | PPARDPPARGPPARAMEN1KMT2A | |
| SCHEMBL6539994 | 0.86 | PPARD (0.52) | PPARDRCE1TAAR1PPARGPPARA | |
| SCHEMBL6539085 | 0.83 | PPARD (0.54) | PPARDRCE1TAAR1PPARGPPARA | |
| SCHEMBL6538975 | 0.82 | PPARD (0.49) | PPARDRCE1TAAR1PPARGPPARA | |
| SCHEMBL6539370 | 0.82 | PPARD (0.47) | PPARDRCE1TAAR1PPARGPPARA | |
| SCHEMBL6540447 | 0.81 | RCE1 (0.47) | PPARDRCE1TAAR1MEN1KMT2A | |
| SCHEMBL6539881 | 0.78 | PPARD (0.51) | PPARDRCE1TAAR1PPARGPPARA | |
| SCHEMBL6539406 | 0.76 | PPARD (0.37) | PPARDRCE1TAAR1PPARGPPARA | |
| SCHEMBL6539671 | 0.76 | PPARD (0.45) | PPARDRCE1TAAR1 | |
| SCHEMBL6539135 | 0.76 | PPARD (0.39) | PPARDRCE1TAAR1PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1583749-A1 | OXAZOLE DERIVATIVES AS INHIBITORS OF CYCLOOXYGENASE | Astellas Pharma Inc. (JP) | 2005-10-12 | — | — | EP | disclosed |
| US-20040157891-A1 | Inhibitor of cox | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-12 | — | — | US | disclosed |
| WO-2004065374-A1 | OXAZOLE DERIVATIVES AS INHIBITORS OF CYCLOOXYGENASE | ASTELLAS PHARMA INC. (JP) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157891-A1 | Inhibitor of cox | PTGS1, PTGS2, PTGES2 | PPARD 1747/4885RCE1 337/4885TAAR1 1264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.